Mega Lifesciences PCL (BKK:MEGA)

Market Cap	30.95B +22.4%
Revenue (ttm)	14.53B +1.5%
Net Income	2.19B +17.6%
EPS	2.51 +17.6%
Shares Out	871.87M
PE Ratio	14.13
Forward PE	13.11
Dividend	1.70 (4.79%)
Ex-Dividend Date	Aug 26, 2026

Volume	536,280
Open	35.50
Previous Close	35.25
Day's Range	35.00 - 35.50
52-Week Range	29.25 - 40.00
Beta	0.36
Analysts	Strong Buy
Price Target	42.71 (+20.31%)
Earnings Date	Nov 13, 2026

About Mega Lifesciences PCL

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods. The company operates through three segments: Brands, Distribution, and Original Equipment Manufacture. It offers wellness and nutrition products, including medical and sports nutrition, general well-being, vitamins, probiotics, herbal medicines, and cough and cold medicines, as well as hair, kid’s, men’...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1982
• Employees: 900
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: MEGA

Financial Performance

In 2025, Mega Lifesciences PCL's revenue was 14.19 billion, a decrease of -7.74% compared to the previous year's 15.39 billion. Earnings were 1.91 billion, a decrease of -4.99%.

Analyst Summary

According to 7 analysts, the average rating for MEGA stock is "Strong Buy." The 12-month stock price target is ฿42.71, which is an increase of 20.31% from the latest price.

Price Target

฿42.71

(20.31% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error